IGC Pharma, Inc.
IGC
$0.325
$0.01866.07%
| Weiss Ratings | IGC - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | IGC - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | IGC - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.38 | |||
| Price History | IGC - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 15.21% | |||
| 30-Day Total Return | -2.78% | |||
| 60-Day Total Return | -10.71% | |||
| 90-Day Total Return | -17.91% | |||
| Year to Date Total Return | -8.96% | |||
| 1-Year Total Return | -2.43% | |||
| 2-Year Total Return | -14.59% | |||
| 3-Year Total Return | -68.14% | |||
| 5-Year Total Return | -20.75% | |||
| 52-Week High % Change | -66.33% | |||
| 52-Week Low % Change | 17.48% | |||
| Price | IGC - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.91 | |||
| 52-Week Low Price | $0.26 | |||
| 52-Week Low Price (Date) | Feb 25, 2025 | |||
| 52-Week High Price (Date) | Apr 04, 2024 | |||
| Valuation | IGC - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 24.42M | |||
| Enterprise Value | 24.22M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.12 | |||
| Earnings Per Share Growth | -50.04% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 19.27 | |||
| Price/Book (Q) | 3.83 | |||
| Enterprise Value/Revenue (TTM) | 19.59 | |||
| Price | $0.33 | |||
| Enterprise Value/EBITDA (TTM) | -2.92 | |||
| Enterprise Value/EBIT | -2.71 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | IGC - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 77.63M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | IGC - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 301 983 0998 | |||
| Address | 10224 Falls Road Potomac, MD 20854 | |||
| Website | igcpharma.com | |||
| Country | United States | |||
| Year Founded | 2005 | |||
| Profitability | IGC - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -722.00% | |||
| Profit Margin | -712.70% | |||
| Management Effectiveness | IGC - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -54.85% | |||
| Return on Equity | -- | |||
| Income Statement | IGC - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 1.24M | |||
| Total Revenue (TTM) | 1.24M | |||
| Revenue Per Share | $0.02 | |||
| Gross Profit (TTM) | 636.00K | |||
| EBITDA (TTM) | -8.30M | |||
| EBIT (TTM) | -8.92M | |||
| Net Income (TTM) | -8.81M | |||
| Net Income Avl. to Common (TTM) | -8.81M | |||
| Total Revenue Growth (Q YOY) | 25.98% | |||
| Earnings Growth (Q YOY) | 67.28% | |||
| EPS Diluted (TTM) | -0.12 | |||
| EPS Diluted Growth (Q YOY) | 73.09% | |||
| Balance Sheet | IGC - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 470.00K | |||
| Cash Per Share (Q) | $0.01 | |||
| Total Current Assets (Q) | 3.05M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 6.26M | |||
| Current Ratio (Q) | 1.148 | |||
| Book Value Per Share (Q) | $0.08 | |||
| Total Assets (Q) | 9.08M | |||
| Total Current Liabilities (Q) | 2.66M | |||
| Total Debt (Q) | 270.00K | |||
| Total Liabilities (Q) | 2.82M | |||
| Total Common Equity (Q) | 6.26M | |||
| Cash Flow | IGC - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -623.00K | |||
| Cash from Financing (TTM) | 4.31M | |||
| Net Change in Cash (TTM) | -908.00K | |||
| Levered Free Cash Flow (TTM) | -4.50M | |||
| Cash from Operations (TTM) | -4.59M | |||
